BECTON DICKINSON and CO

Discover why Becton, Dickinson & Co. is a standout healthcare stock—diversified devices, high‑margin diagnostics, and value‑based contracts driving future growth.

Discover how Becton, Dickinson (BDX) balances low debt, strong cash flow, and high R&D to capture growing diagnostics demand amid rising rates and digital‑health regulation.

BDX insider sale: CFO sells few shares yet keeps 8,000+ holdings, showing confidence in Becton‑Dickinson’s medical tech growth and market prospects.

How Becton Dickinson’s post‑merger shift to consumables and data analytics boosts diagnostics margins and urinalysis ROI.

BD’s latest Form 144 is a routine share sale, not a strategic shift, yet the company’s strong revenue, cash flow and investment in point‑of‑care and remote monitoring technologies keep it well‑positioned to drive better clinical outcomes and shareho…

BD’s 1,330‑share Form 144 sale shows a routine insider exercise—yet it hints at executive sentiment, compensation structure, and governance trends in the diagnostics market.

BDX’s CEO Thomas Polen’s new stock purchases, sales, and SAR vesting reveal a deeper executive stake in Becton, Dickinson’s future.

BDX’s Q2 2026 report shows steady revenue, strong margins, and a spin‑off that fuels share buybacks and debt cuts—boosting cash, liquidity, and growth prospects.

BD’s Q3 FY2026 earnings show modest yet steady growth—$5B revenue, 5% YoY rise, and 44% free cash‑flow jump—underscoring its focused strategy and resilience in a shifting reimbursement landscape.

BD’s Brazil partnership boosts semaglutide access, cuts costs, and fuels $120 M revenue, while quarterly dividends and Rule 144 compliance reinforce investor confidence.